The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults. The population pharmacokinetic analysis was conducted using plasma concentrations in 132 Japanese adolescent and 135 adult patients with schizophrenia (including 20 older adults [≥65 years] patients), and 49 healthy adults. The blonanserin population pharmacokinetics was described using a two-compartment model with first-order absorption with lag time. Relative bioavailability decreased in fasted conditions and with concomitant CYP3A4 inducer use. Apparent clearance in older adult was lower than adult and adolescent. Simulation revealed similar plasma exposures between adolescents and adults and slightly larger in older adults. Bayesian estimates of apparent clearance suggested no effects of age in adolescents between 12 and 18 years old. Together, these results reveal the pharmacokinetic characteristics of blonanserin over a wide age range and support the appropriateness of the approved dosing regimen for adolescent patients with schizophrenia in Japan.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.dmpk.2024.101043 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Multilayer network instability underlying persistent auditory verbal hallucinations in schizophrenia.
Psychiatry Res
December 2024
Department of Psychiatry, Sir Run-Run Shaw Hospital, School of Medicine, Zhejiang University, Hangzhou, PR China. Electronic address:
Background: Auditory verbal hallucinations (AVHs) in schizophrenia (SCZ) are linked to brain network abnormalities. Resting-state fMRI studies often assume stable networks during scans, yet dynamic changes related to AVHs are not well understood.
Methods: We analyzed resting-state fMRI data from 60 SCZ patients with persistent AVHs (p-AVHs), 39 SCZ patients without AVHs (n-AVHs), and 59 healthy controls (HCs), matched for demographics.
DDEvENet: Evidence-based ensemble learning for uncertainty-aware brain parcellation using diffusion MRI.
Comput Med Imaging Graph
January 2025
University of Electronic Science and Technology of China, Chengdu, Sichuan, China. Electronic address:
In this study, we developed an Evidential Ensemble Neural Network based on Deep learning and Diffusion MRI, namely DDEvENet, for anatomical brain parcellation. The key innovation of DDEvENet is the design of an evidential deep learning framework to quantify predictive uncertainty at each voxel during a single inference. To do so, we design an evidence-based ensemble learning framework for uncertainty-aware parcellation to leverage the multiple dMRI parameters derived from diffusion MRI.
View Article and Find Full Text PDFPopulation pharmacokinetics of blonanserin in Japanese adolescent and adult patients with schizophrenia.
Drug Metab Pharmacokinet
November 2024
Clinical Research, Drug Development Division, Sumitomo Pharma Co., Ltd., 33-94, Enoki-cho, Suita, Osaka, 564-0053, Japan. Electronic address:
The second-generation antipsychotic blonanserin is a highly selective, full antagonist of dopamine D and D and serotonin 5-HT receptors. It is currently prescribed for patients with schizophrenia in Japan. We aimed to develop a population pharmacokinetic model of oral blonanserin, including data from 12 to 77 years old patients, to assess the covariates that influence blonanserin pharmacokinetics and evaluate appropriate dosage regimens in adolescents versus adults.
View Article and Find Full Text PDFThe Challenging Problems of Cancer and Serious Mental Illness.
Curr Psychiatry Rep
January 2025
Institute of Psychiatry, Department of Neuroscience and Rehabilitation, University of Ferrara, Via Fossato di Mortara 64a, Ferrara, 44121, Italy.
PURPOSE OF REVIEW: Patients with Serious Mental Illness (SMI) are reported to be at higher risk for somatic disorders (e.g. cardiovascular and metabolic diseases) and higher mortality, compared to the general population, because of the consequences of SMI including psychotropic medication side effects, sedentary and unhealthy lifestyle, difficult access to physical health care.
View Article and Find Full Text PDFPatient-reported outcome measures to assess mental and physical health status, functionality, and quality of life in patients with major depression or schizophrenia.
J Patient Rep Outcomes
January 2025
Parc Sanitari Sant Joan de Déu, General Hospital, C/ Doctor Antoni Pujadas 42, Sant Boi de Llobregat, Barcelona, E-08830, Spain.
Background: Patient-reported outcomes measures (PROMs) are standardized self-administered tools that assess the patient's opinion on the level of health, quality of life, and disability among other aspects. The objective of this study was to gather information on physical and mental health in patients with major mental illness using PROMs.
Methods: This was an observational, naturalistic, prospective study carried out in adult stabilized outpatients attended at nine Adult Mental Health Centers in Barcelona, Spain.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!